Zoetis Inc. (ZTS) To Go Ex-Dividend on July 20th

Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Wednesday, May 20th. Stockholders of record on Monday, July 20th will be given a dividend of 0.53 per share on Tuesday, September 1st. This represents a c) annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th.

Zoetis has increased its dividend payment by an average of 0.2%annually over the last three years and has raised its dividend annually for the last 14 consecutive years. Zoetis has a payout ratio of 31.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect Zoetis to earn $7.35 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 28.8%.

Zoetis Stock Performance

Shares of ZTS stock opened at $76.44 on Friday. The stock has a fifty day moving average of $77.33 and a 200 day moving average of $106.03. Zoetis has a 52 week low of $71.47 and a 52 week high of $160.48. The firm has a market capitalization of $32.05 billion, a price-to-earnings ratio of 12.68, a PEG ratio of 1.20 and a beta of 0.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter last year, the firm earned $1.48 EPS. The business’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis will post 6.87 earnings per share for the current year.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis was named as title sponsor of PawsitiveIntelligence.ai, adding a small brand-visibility and industry-partnership angle. Pawsitive Holdings Announces Zoetis as Title Sponsor of PawsitiveIntelligence.ai
• Positive Sentiment: Some commentary argued Zoetis offers an attractive risk-reward setup, suggesting a more constructive long-term view despite recent volatility. Zoetis: An Attractive Risk-Reward Opportunity
• Neutral Sentiment: Zoetis’ upcoming second-quarter earnings report is getting attention, with analysts expecting modest growth and investors watching for updated guidance and commentary on diagnostics demand. Zoetis Earnings Preview: What to Expect
• Neutral Sentiment: Zoetis announced it will acquire VitalRADS, a veterinary teleradiology platform, which could support its diagnostics strategy and AI-enabled offerings. Zoetis Gains as VitalRADS Deal Boosts Diagnostics Narrative
• Negative Sentiment: Multiple law firms issued reminders and investor alerts tied to a securities class action against Zoetis, reinforcing concerns about litigation risk and possible reputational damage. Deadline Alert for CALX, AVAV, ZTS, LCID
• Negative Sentiment: Additional class-action notices specifically target Zoetis shareholders, underscoring that the lawsuit remains an active overhang for the stock. ZTS Shareholder Alert
• Negative Sentiment: The legal backdrop follows earlier reports alleging investor harm and reminding shareholders of the same July 27 deadline, keeping sentiment cautious. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.